Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Hope sputters for emerging anti-TIGIT drug class

Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

By Kelly Bilodeau • Sept. 5, 2023

4 modernized functions every sponsor needs for study startup

Explore four modern tech capabilities designed to help decrease cycle times, improve processes and compliance and mitigate site burdens.

By Stuart Cotter, VP Product Innovation and Strategy, Advarra • Sept. 5, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Why pharma isn’t done tackling migraines

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

By Kelly Bilodeau • Aug. 28, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Behind Flagship Pioneering’s triumphs and tribulations

From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

By Karissa Waddick • Aug. 18, 2023

How an AstraZeneca exec is leading the charge in the next immuno-oncology era

The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

By Michael Gibney • Aug. 17, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.

By Kelly Bilodeau • Aug. 14, 2023

What pharma companies are getting wrong about drug repositioning

Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.

By Alexandra Pecci • Aug. 9, 2023

Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

By Taren Grom and Meagan Parrish • Aug. 9, 2023

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

By Michael Gibney • Aug. 8, 2023

Pharma’s rocky love affair with oxytocin

Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.

By Kelly Bilodeau • Aug. 7, 2023

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023

As Barbie breaks the box office, women’s health investment explodes

Much like the year she first graced store shelves, Barbie has taken over the world. But now, the women's health landscape looks a whole lot different.

By Karissa Waddick • Aug. 2, 2023

A pharma banking on the success of past blockbusters

180 Life Sciences is on a mission to see if the anti-TNF technology that produced a blockbuster could work for a range of other conditions.

By Kelly Bilodeau • July 31, 2023

For Merck, understanding maternal mortality is the first step toward equity

Merck has invested for more than a decade in reducing maternal death rates in the U.S. and globally. Now for the next chapter.

By Michael Gibney • July 25, 2023

In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

By Alexandra Pecci • July 25, 2023